Concurrent Investment Advisors LLC Invests $238,000 in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Concurrent Investment Advisors LLC has invested approximately $238,000 in Aurinia Pharmaceuticals, purchasing 28,070 shares during the second quarter.
• Aurinia Pharmaceuticals has received mixed ratings from analysts, with a target price ranging from $9.00 to $17.00, leading to a consensus rating of "Moderate Buy."
• Insider activity has been notable, with director Kevin Tang purchasing 200,000 shares at an average cost of $11.68 per share, increasing his ownership stake.

Concurrent Investment Advisors LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 28,070 shares of the biotechnology company's stock, valued at approximately $238,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC increased its stake in shares of Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after acquiring an additional 1,744 shares during the period. MAI Capital Management acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter worth about $39,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter worth about $60,000. Xponance Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter worth about $82,000. Finally, Kazazian Asset Management LLC acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter worth about $84,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AUPH. Weiss Ratings reiterated a "hold (c)" rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. Royal Bank Of Canada upped their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. Finally, HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $13.00.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang purchased 200,000 shares of the stock in a transaction dated Tuesday, August 5th. The shares were acquired at an average cost of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the transaction, the director directly owned 11,329,500 shares of the company's stock, valued at $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have purchased 1,300,000 shares of company stock valued at $13,590,000 in the last quarter. 12.20% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Stock Up 2.5%

AUPH stock opened at $11.84 on Tuesday. The company's 50 day simple moving average is $12.05 and its 200-day simple moving average is $9.67. The firm has a market capitalization of $1.56 billion, a PE ratio of 27.54 and a beta of 1.25. Aurinia Pharmaceuticals Inc has a 12 month low of $6.55 and a 12 month high of $13.54. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.